Skip to content

Replimune Group REPL Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Summit Therapeutics logo
Summit TherapeuticsSMMT
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Incyte logo
IncyteINCY
GRAIL, Inc. logo
GRAIL, Inc.GRAL
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's convertible preferred stock outstanding shares?
Replimune Group (REPL) reported convertible preferred stock outstanding shares of 0 in Q4 2025.